CLINICAL_TRIALS trial_result · 2020-10-06

Clinical Trial Update: Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP [Phase 1]

View source ↗

Summary

Phase 1 study reporting safety and pharmacokinetics of a single 3.36 mg dose of CCH in subjects with Edematous Fibrosclerotic Panniculopathy; completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Edematous Fibrosclerotic Panniculopathy | Phase 1 | Status: COMPLETED | Results posted: 2020-10-06